Navigation Links
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Date:12/20/2007

Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507

for the Treatment of Sarcoma

COPENHAGEN, Denmark, December 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

About Sarcoma

Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve, cartilage, blood vessel and deep skin tissue. Due to the wide variety of types of sarcoma, the disease is often difficult to detect, is often misdiagnosed and is complex to treat. Sarcoma is a rare type of cancer with US incidence of approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000 are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Seeks Exclusion Order Barring Importation of CryoCath,s Cryoablation ... Inc. (Nasdaq:,CRYO), a medical device company focused on ... has filed a formal complaint with the,United States ... has engaged in unfair trade practices by infringing ...
... HAYWARD, Calif., Feb. 28 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... December 31, 2007., Net losses for the quarter and ... or $0.22 and $0.69 per share, compared to $4.6,million and ... same,periods for the prior year., Revenues were $5.6 million ...
... Double-Digit Year-over-Year Revenue Increases, from Antibody Technology (up 28%); ... 20% Year-over-Year Growth in Food Pathogen Testing ... (Nasdaq: SDIX ) - reported that total revenues ... an increase of 4% over the fourth,quarter of 2006. ...
Cached Biology Technology:CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 2Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 5Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 6Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 2Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 3Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 4Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 5Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 6Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 7Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 8Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 9Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 10Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 11Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 12
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
(Date:12/10/2014)... San Diego has launched an innovative trust network and collaboration ... among social service and care providers by enabling them to ... from the Alliance Healthcare Foundation to expand to organizations serving ... "Live Well San Diego" partner on December 11 th ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... of Toronto that stimulates the muscles of patients with spinal ... condition is not expected to improve. , U of ... process that sends controlled bursts of electricity through the skin ... stride length and overall walking speed. , "This is a ...
... methane-producing bacteria frozen at the bottom of Greenland's two-mile ... similar bacterial life on Mars. , Methane is a ... and Mars. If a class of ancient microbes called ... scientists have proposed, then unmanned probes to the Martian ...
... research by a team of scientists in France and ... host receptor proteins that enable Rickettsia conorii, the Mediterranean ... bacterium interacts with the cells of its host could ... related pathogens, including Rocky Mountain spotted fever and ...
Cached Biology News:Microbes under Greenland Ice may be preview of what scientists find under Mars' surface 2Microbes under Greenland Ice may be preview of what scientists find under Mars' surface 3How Rickettsial pathogens break into cells 2
... The PRO S-7 stirrers deliver ... housing channels fluids away from ... features easy-to-use controls which allow ... 7"x7" ceramic tops feature a ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... This kit is designed for the ... large vector plasmids at any position (for ... included loxP-PGK-gb2-neo-loxP cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: